Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Shares Slide 5 Percent on News of CEO Departure

NEW YORK, April 4 (GenomeWeb News) - Shares of Transgenomic were down 5.63 percent, or $.04, at $.67 in mid-afternoon trading after the company said CEO Collin D'Silva has resigned.

 

As GenomeWeb News reported this morning, Michael Summers, the company's chief financial officer, has taken over as interim CEO until a new chief executive has been found. He also remains CFO.

 

D'Silva will remain chairman of the board and will manage "strategic customer relationships" and evaluate corporate strategic alternatives.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more